91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料 survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
In this article, 91黑料 experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
-
In this article, CON’s Jack Martin discusses the direction obesity drug research is heading, and the challenges faced by researchers.
-
In this article, 91黑料's Jack Martin explores the impact of comorbidities on obesity therapeutic development including strategic and innovative approaches to therapeutic development and clinical trials design.
-
Recent advancements in obesity treatments have spotlighted the field for healthcare providers and developers. In this article from Drug Discovery World, 91黑料 experts share insights on the clinical trials landscape for obesity and why patient centricity is key to overcoming common challenges in the sector.
-
In an interview with Contract Pharma, 91黑料’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
91黑料’s Simon Bruce, Vice President of Internal Medicine and Drug Development Solutions sits down for a Q&A with Pharmaceutical Executive and gives an overview on the obesity survey carried out by 91黑料 in January 2024 and what it suggests about the state of the obesity-related pipeline.
-
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
This news piece from The Clinical Trial Vanguard provides an overview of the findings from 91黑料’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
